Cardiometabolic multimorbidity has become an increasingly urgent global public health concern. Patients rarely develop these disorders in isolation; hypertension begets atherosclerosis, diabetes accelerates vascular injury, and stroke and ischemic heart disease frequently follow. What ties this cluster together, the review emphasizes, is endothelial dysfunction, a failure of the single-cell layer that lines every blood vessel in the body. The endothelium is far more than a passive barrier. It regulates vascular tone through nitric oxide signaling, controls inflammatory adhesion of immune cells, maintains the integrity of barriers such as the blood-brain barrier, and orchestrates tissue repair. When it falters, the consequences ripple across the entire cardiovascular and metabolic system, which is why endothelial dysfunction serves both as an early warning marker and as a central driver of disease progression.

The review’s central proposition is that endothelial cells communicate their state of health, or distress, to distant tissues through extracellular vesicles, particularly exosomes. These nanoscale membrane-bound particles, typically ranging from roughly 30 to 150 nanometers in diameter, are released when multivesicular bodies within the cell fuse with the plasma membrane. Far from being cellular debris, exosomes are carefully sorted packages carrying a molecular cargo that mirrors and modulates the physiology of the parent cell. Endothelial-derived exosomes, abbreviated ECs-exo in the review, transport microRNAs, long non-coding RNAs, circular RNAs, proteins, and lipids to recipient cells, where these molecules can reprogram gene expression, alter signaling pathways, and shift cellular behavior.

The mechanistic detail assembled by the Chongqing team is considerable. Dysregulated exosomal cargos, the authors report, propagate vascular inflammation, insulin resistance, and fibrotic remodeling across cardiometabolic disease. Inflammatory cascades involving Toll-like receptor 4 signaling, adhesion molecules such as ICAM-1 and VCAM-1, and mediators like high mobility group box 3 protein and oxidized low-density lipoprotein are amplified or dampened by the exosomal payload. Signaling hubs including the MAPK and ERK pathways, protein kinase C-alpha, phosphatase and tensin homologue, forkhead box protein O1, and hypoxia-inducible factor-1alpha appear repeatedly in the regulatory networks the review describes. Hypoxia-inducible factor-1alpha in particular links oxygen deprivation, a hallmark of ischemic heart disease and stroke, to exosomal reprogramming that can either aggravate injury or, under the right conditions, promote adaptation and repair.

Not all endothelial exosomes are harbingers of disease. The review highlights a protective side of the axis: exosomal microRNAs released by healthy endothelium support vascular repair and suppress pathological inflammation. Endothelial progenitor cells, which participate in vessel regeneration, release vesicles enriched with pro-angiogenic and anti-inflammatory microRNAs that can enhance nitric oxide production, reduce endothelin-1-driven vasoconstriction, and stabilize vulnerable plaques. Molecules such as heme oxygenase-1, Krüppel-like factor 2, and vascular endothelial growth factor feature in these restorative programs, while chemokine receptor type 4 helps guide reparative vesicles to sites of injury. In models of cerebral ischemia such as middle cerebral artery occlusion, endothelial and progenitor-derived vesicles have been shown to protect the blood-brain barrier, in part by preserving tight junction proteins like zona occludens 1 and modulating von Willebrand factor release and angiopoietin-2 signaling.

This dual nature, pathological messenger and therapeutic agent, is precisely what makes the exosomes-X axis clinically attractive. On the diagnostic front, the review catalogs circulating endothelial exosome signatures with potential utility for early detection, prognosis, and disease stratification. Because exosomes in the blood carry molecular fingerprints of their cells of origin, profiling their microRNA, protein, and lipid content offers a non-invasive window into vascular health. A blood test that reads the endothelial exosome cargo could, in principle, identify patients at risk of developing multimorbidity long before symptoms appear, distinguish between inflammatory and metabolic disease subtypes, and track response to therapy over time. The authors argue that such signatures hold genuine promise as biomarkers, though they note that standardization of isolation and analytical methods remains an obstacle to clinical deployment.

On the therapeutic side, the review evaluates an emerging strategy: engineering endothelial exosomes to deliver therapeutic cargos and thereby restore vascular homeostasis. Exosomes offer several advantages over synthetic drug carriers. They are naturally biocompatible, cross biological barriers including the blood-brain barrier, can be surface-functionalized with targeting ligands, and can be loaded with RNA therapeutics, anti-inflammatory proteins, or small molecules. The authors describe multimodal formulations and advanced bioengineering platforms designed to tune vesicle tropism, cargo loading efficiency, and release kinetics. Engineered vesicles derived from healthy endothelium or endothelial progenitor cells could, for example, deliver anti-inflammatory microRNAs to atherosclerotic plaques or insulin-sensitizing cargos to metabolically active tissues, addressing several facets of multimorbidity with a single platform.

The concept of theragnostics, the fusion of therapy and diagnostics in one system, runs throughout the review. Because the same exosomal signatures that signal disease can be engineered into delivery vehicles that report on their biodistribution, ECs-exo could enable truly individualized treatment: profile the patient’s vesicle cargo, identify the dominant pathological pathway, select or engineer a matching therapeutic vesicle, and monitor the molecular response in circulation. The authors position this integrated approach as a way to improve diagnosis, prognosis, and personalized management of cardiometabolic multimorbidity, a condition whose complexity has largely defeated single-target drugs.

The review is candid about the challenges that stand between laboratory promise and bedside impact. Isolation and characterization protocols vary widely across studies, cargo sorting mechanisms are not yet fully mapped, dose standardization for vesicle therapeutics is unresolved, and large-scale manufacturing under good manufacturing practice conditions remains a formidable engineering problem. Distinguishing protective from pathological vesicle populations within a heterogeneous circulating pool is another unsolved puzzle. Nevertheless, the convergence of mechanistic insight, biomarker discovery, and bioengineering capability documented in the review suggests that the field is approaching an inflection point.

Funded by the National Natural Science Foundation of China, the Natural Science Foundation of Chongqing, and a Chongqing medical scientific research joint project, the work reflects a broader international push to understand extracellular vesicles as the body’s intercellular internet. If the exosomes-X axis framework proves correct, the endothelium’s nanoscale messengers may soon serve simultaneously as the earliest alarm for cardiometabolic disease, the yardstick of its progression, and the vehicle that reverses it. For the millions of people living with overlapping cardiovascular and metabolic disorders, that would represent a fundamental shift from managing separate diseases to treating the vascular system as the integrated whole it truly is.

Subject of Research: Endothelial cell-derived exosomes as diagnostic biomarkers and engineered therapeutics for cardiometabolic multimorbidity

Article Title: Exosomes-X axis: endothelial-derived extracellular vesicles for precision diagnosis and therapy in cardiometabolic multimorbidity

Article References: Tang, F., Zhu, S.-C., Zhou, H.-M., Liu, M., Yuan, W.-X., & Qiu, X.-W. (2026). Exosomes-X axis: endothelial-derived extracellular vesicles for precision diagnosis and therapy in cardiometabolic multimorbidity. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08946-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08946-w

Keywords: exosomes, endothelial cells, extracellular vesicles, cardiometabolic multimorbidity, type 2 diabetes, hypertension, atherosclerosis, stroke, microRNAs, endothelial dysfunction, targeted therapy, theragnostics

Researchers analyzed how sleep quality and frailty relate to the co-occurrence of cardiometabolic disorders, focusing on patterns that emerge when both factors are present at once. Using statistical modeling suited for observational data, the team assessed whether the combined effect of sleep impairment and frailty exceeds what would be expected if each acted alone.

The findings point to independent associations in both directions. In other words, older participants with worse sleep quality were more likely to show cardiometabolic multimorbidity, and those with greater frailty also faced higher odds. This dual relationship strengthens the biological plausibility of the sleep–health link in late life.

But the headline result is synergy. The study suggests that the joint presence of insufficient or low-quality sleep and frailty corresponds to a disproportionately greater burden of cardiometabolic multimorbidity. Such interactions matter because they imply that tackling only one factor may leave a major portion of risk untouched.

From a mechanistic perspective, poor sleep can disrupt metabolic regulation, impair glucose homeostasis, and contribute to inflammatory signaling, all of which can accelerate vascular and metabolic dysfunction. Frailty, meanwhile, reflects reduced physiological reserve—often shaped by chronic inflammation, muscle loss, and stress-axis dysregulation—creating a vulnerable platform for cardiometabolic disease to cluster.

The cross-sectional design cannot prove causality, but it helps map where risk concentrates in real-world aging. The authors argue that clinicians and public health programs should consider sleep quality and frailty together, rather than treating them as separate problems.

In a Viral science news framing, the study’s message is clear: “better sleep” and “less frailty” may be more connected than previously assumed, potentially offering a more coordinated prevention strategy for seniors facing multiple cardiometabolic conditions.

Subject of Research: Sleep quality, frailty, and cardiometabolic multimorbidity in Chinese elderly population (cross-sectional analysis)

Article Title: Independent and synergistic associations of sleep quality and frailty with cardiometabolic multimorbidity: a cross-sectional analysis in Chinese elderly population

Article References: Bing, S., Liu, W., Song, S. et al. Independent and synergistic associations of sleep quality and frailty with cardiometabolic multimorbidity: a cross-sectional analysis in Chinese elderly population. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07985-8

Image Credits: AI Generated

DOI: 10.1186/s12877-026-07985-8

Keywords: Sleep quality; frailty; cardiometabolic multimorbidity; older adults; cross-sectional analysis

The concept of dynapenic obesity, characterized by the coexistence of diminished muscle strength (dynapenia) and obesity, has increasingly demanded scientific attention. While obesity alone is a well-established risk factor for cardiometabolic diseases, the overlay of muscular weakness may act synergistically to drive disease onset and progression. This research, led by Wang, N., Wang, T., and Jia, X., undertook a prospective cohort study design to map the trajectories of CMD in individuals exhibiting dynapenic obesity, providing more granular insight than previously available cross-sectional data or small-scale analyses.

Methodologically, the study employed robust muscle strength assessments alongside standard anthropometric measures to define dynapenic obesity accurately. Participants were followed longitudinally to capture new incidences or worsening of cardiometabolic conditions, allowing researchers to parse out temporal relationships. The large sample size and extended follow-up enhanced the statistical power and validity of the findings, positioning this study as a keystone in the emerging field exploring the nexus between musculoskeletal health and metabolic syndrome components.

One of the most striking revelations from the data is the pronounced increase in cardiometabolic disease incidence among individuals with dynapenic obesity compared to those with either normal body composition or obesity alone. This suggests that muscle strength deficits may not merely compound obesity’s risks but could catalyze pathological mechanisms that accelerate disease processes. In effect, the presence of dynapenia transforms the risk landscape for patients, markedly altering disease trajectories and clinical outcomes.

Delving into the biological underpinnings, the study places particular emphasis on systemic inflammation and dyslipidemia as potential mechanisms. CRP, a sensitive biomarker of inflammation, was found to be significantly elevated in the dynapenic obese cohort, demonstrating its mediating role. Chronic low-grade inflammation is long implicated in endothelial dysfunction, insulin resistance, and atherogenesis—all hallmarks of cardiometabolic diseases. This research solidifies CRP’s position not just as a risk marker but as an active participant linking muscle weakness, obesity, and metabolic derangements.

Similarly, the atherogenic index of plasma, a logarithmic ratio of triglycerides to high-density lipoprotein cholesterol, emerged as another critical mediator. Elevated AIP indicates a lipid profile highly conducive to atheroma formation and cardiovascular risk. The study reveals that dynapenic obesity is associated with adverse alterations in lipid metabolism, evidenced by elevated AIP levels, which could mechanistically facilitate rapid progression of CMD through enhanced atherogenesis.

The integration of inflammatory and lipid-mediated pathways elucidated in this research underscores the multifaceted nature of dynapenic obesity as a cardiometabolic accelerator. These findings have profound implications for clinical practice, pinning down potential biomarkers for early identification of at-risk populations. Moreover, they offer rationale for multifactorial intervention strategies aimed at both preserving muscle strength and optimizing metabolic parameters.

Public health perspectives also gain new insights from this investigation. With aging populations worldwide and the epidemic rise of obesity, dynapenic obesity may become an increasingly prevalent phenotype warranting targeted screening and tailored management approaches. The study’s findings press the urgency to design community and clinical programs that emphasize resistance training and nutritional optimization to mitigate the dual threats posed by sarcopenia and adiposity.

This research also opens avenues for pharmacological innovation. Agents capable of modulating systemic inflammation or improving lipid profiles in the context of dynapenic obesity may offer new therapeutic promises for curbing CMM progression. A multidisciplinary approach, integrating endocrinology, geriatrics, nutrition science, and physical therapy, is paramount in translating these findings into meaningful health outcomes.

An intriguing aspect warrants further exploration: the interaction between dynapenic obesity and other emerging cardiometabolic risk factors, including gut microbiota perturbations, mitochondrial dysfunction, and hormonal dysregulation. Elucidating these connections may enrich our understanding and lead to more comprehensive intervention frameworks.

Additionally, the longitudinal design of this study sets a benchmark for future investigations. By following subjects over time, the researchers could capture the dynamic interplay between muscle strength, fat mass, inflammation, lipids, and disease onset. This temporal dimension is critical for unraveling causality and not merely associative correlations, which often confound cross-sectional studies in this domain.

The clinical implications extend to diagnostic protocols. Routine incorporation of muscle strength testing, alongside traditional metabolic panels, may revolutionize risk assessment paradigms in outpatient settings. Early identification of dynapenic obesity could pivot treatment trajectories towards more personalized and effective regimens, potentially stalling or reversing cardiometabolic disease progression.

From a mechanistic standpoint, the study sheds light on how muscle weakness may exacerbate obesity-related metabolic dysfunctions. Skeletal muscle plays a pivotal role in glucose uptake and lipid oxidation; thus, declines in muscle function may impair these processes, heightening insulin resistance and systemic lipid abnormalities observed in dynapenic obese individuals.

Equally important is the study’s contribution to health equity discourse. Dynapenic obesity disproportionately affects older adults and socioeconomically disadvantaged groups who may have limited access to interventions that bolster muscle health. Recognizing this disparity is critical for framing public health policies and resource allocation that address fundamental causes rather than just clinical consequences.

The narrative emerging from this research reframes cardiometabolic disease risk, moving beyond classical obesity paradigms to a more nuanced appreciation of body composition, muscular fitness, and inflammatory milieu. This represents a paradigm shift with broad ramifications for research, clinical care, and population health strategies.

In conclusion, the pioneering work by Wang and colleagues marks a seminal advance in our comprehension of dynapenic obesity as a formidable promoter of cardiometabolic multimorbidity progression. By framing the biological pathways involving CRP and AIP as mediating conduits, the study inspires new horizons for preventative and therapeutic innovation. As the global burden of cardiometabolic diseases continues to escalate, integrating muscle and metabolic health into a unified framework is indispensable for crafting effective interventions and ultimately improving patient outcomes.

Subject of Research: The association between dynapenic obesity and the incidence and progression trajectory of cardiometabolic diseases, including the mediating roles of C-reactive protein (CRP) and the atherogenic index of plasma (AIP).

Article Title: Dynapenic obesity associated with incidence and progression trajectory of cardiometabolic diseases: a prospective cohort study.

Article References:
Wang, N., Wang, T., Jia, X. et al. Dynapenic obesity associated with incidence and progression trajectory of cardiometabolic diseases: a prospective cohort study. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01831-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41366-025-01831-4